Other Species / Isoforms
  ATF-2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T52-p
HKHKHEMtLKFGPAR
Upstream
Downstream
2 1
Effects on Modified Protein
  • intracellular localization
Effects on Biological Processes:
  • apoptosis, inhibited
  • carcinogenesis, induced
  • cell adhesion, inhibited
  • cell growth, induced
  • cell motility, induced
  • transcription, induced
  • transcription, inhibited
Kinase, in vitro:
  • PKCE (human)
Putative in vivo kinases:
  • PKCE (human)
ATF-2 (human) HKHKHEMtLKFGPAR T52-p
ATF-2 (mouse) HKHKHEMTLKFGPAR T34
ATF-2 (rat) HKHKHEMTLKFGPAR T34
S62-p
FGPARNDsVIVADQt
Upstream
Downstream
2 38
Effects on Modified Protein
  • activity, induced
  • protein stabilization
Effects on Biological Processes:
  • transcription, induced
Kinase, in vitro:
  • PKACA (cow)
  • VRK1 (human)
Putative in vivo kinases:
  • VRK1 (human)
ATF-2 (human) FGPARNDsVIVADQt S62-p
ATF-2 (mouse) FGPARNDsVIVADQt S44-p
ATF-2 (rat) FGPARNDSVIVADQt S44
T69-p
sVIVADQtPtPtRFL
Upstream
Downstream
31 105
ATF-2 (human)
T69-p
ATF-2 (mouse)
T51-p
ATF-2 (rat)
T51-p
Effects on Modified Protein
  • activity, induced
  • protein degradation
  • protein stabilization
  • ubiquitination
Effects on Biological Processes:
  • signaling pathway regulation
  • transcription, altered
  • transcription, induced
Kinase, in vitro:
  • ERK1 (human)
  • JNK1 (human)
  • JNK2 (human)
  • P38A (human)
  • P38A (mouse)
  • P38B (human)
  • PLK3 (human)
Putative in vivo kinases:
  • JNK1 (human)
  • JNK2 (human)
  • P38A (human)
  • P38B (human)
Regulatory protein:
  • Akt1 (human)
  • CAMK4 (human)
  • DVL1 (human)
  • Ku70 (human)
  • Myc (human)
  • RALA (human)
  • TMEM88 (human)
Treatment
  • 15d-PGJ2
  • angiotensin_2
  • anisomycin
  • anti-CD3
  • caffeine
  • cycloheximide
  • dasatinib
  • EGF
  • high_cell_density
  • ionizing_radiation
  • ischemia
  • lapatinib
  • low_cell_density
  • MG132
  • MMS
  • nocodazole
  • okadaic_acid
  • phorbol_ester
  • PP2
  • retinoic_acid
  • SB202190
  • SB203580
  • serum
  • sorbitol
  • SP600125
  • TNF
  • U0126
  • UV
ATF-2 (human) sVIVADQtPtPtRFL T69-p
ATF-2 (mouse) sVIVADQtPtPtRFL T51-p
ATF-2 (rat) SVIVADQtPtPtRFL T51-p
T71-p
IVADQtPtPtRFLkN
Upstream
Downstream
50 88
ATF-2 (human)
T71-p
ATF-2 (mouse)
T53-p
ATF-2 (rat)
T53-p
Effects on Modified Protein
  • activity, induced
  • protein degradation
  • protein stabilization
  • ubiquitination
Effects on Biological Processes:
  • cell cycle regulation
  • cell growth, altered
  • signaling pathway regulation
  • transcription, altered
  • transcription, induced
Kinase, in vitro:
  • ERK1 (human)
  • ERK2 (human)
  • JNK1 (human)
  • JNK1 (mouse)
  • JNK2 (human)
  • P38A (human)
  • P38A (mouse)
  • P38B (human)
  • P38G (human)
  • PLK3 (human)
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
  • JNK1 (human)
  • JNK2 (human)
  • P38A (human)
  • P38B (human)
Regulatory protein:
  • Akt1 (human)
  • ATF7 iso5 (human)
  • CAMK4 (human)
  • DVL1 (human)
  • HBpX (retrovirus)
  • Ku70 (human)
  • Myc (human)
  • PRP4 (human)
  • RALA (human)
  • TMEM88 (human)
Treatment
  • 15d-PGJ2
  • angiotensin_2
  • anisomycin
  • anti-CD3
  • anti-CD3/CD28
  • anti-TNFalpha
  • caffeine
  • CTGF
  • cycloheximide
  • dasatinib
  • EGF
  • glibenclamide
  • heating
  • high_cell_density
  • IL-13
  • IL-4
  • ionizing_radiation
  • ischemia
  • lapatinib
  • low_cell_density
  • MG132
  • MMS
  • nocodazole
  • okadaic_acid
  • PD184352
  • phorbol_ester
  • PP2
  • PP3
  • retinoic_acid
  • SB202190
  • SB203580
  • serum
  • sorbitol
  • SP600125
  • SU6656
  • testosterone
  • TNF
  • U0126
  • UV
ATF-2 (human) IVADQtPtPtRFLkN T71-p
ATF-2 (mouse) IVADQtPtPtRFLKN T53-p
ATF-2 (rat) IVADQtPtPtRFLKN T53-p
T73-p
ADQtPtPtRFLkNCE
Upstream
Downstream
4 17
Effects on Modified Protein
  • activity, induced
  • protein stabilization
Effects on Biological Processes:
  • transcription, induced
Kinase, in vitro:
  • VRK1 (human)
Putative in vivo kinases:
  • VRK1 (human)
Regulatory protein:
  • CAMK4 (human)
ATF-2 (human) ADQtPtPtRFLkNCE T73-p
ATF-2 (mouse) ADQtPtPtRFLKNCE T55-p
ATF-2 (rat) ADQtPtPtRFLKNCE T55-p
K77-ub
PtPtRFLkNCEEVGL
0 1
ATF-2 (human) PtPtRFLkNCEEVGL K77-ub
ATF-2 (mouse) PtPtRFLKNCEEVGL K59
ATF-2 (rat) PtPtRFLKNCEEVGL K59
S90-p
GLFNELAsPFENEFk
Upstream
5 28
Kinase, in vitro:
  • JNK1 (human)
  • JNK2 (human)
Putative in vivo kinases:
  • JNK1 (human)
Treatment
  • anisomycin
  • ischemia
  • TNF
ATF-2 (human) GLFNELAsPFENEFk S90-p
ATF-2 (mouse) GLFNELAsPFENEFK S72-p
ATF-2 (rat) GLFNELASPFENEFK S72
K97-ac
sPFENEFkKASEDDI
0 1
ATF-2 (human) sPFENEFkKASEDDI K97-ac
ATF-2 (mouse) sPFENEFKKASEDDI K79
ATF-2 (rat) SPFENEFKKASEDDI K79
K97-ub
sPFENEFkKASEDDI
0 1
ATF-2 (human) sPFENEFkKASEDDI K97-ub
ATF-2 (mouse) sPFENEFKKASEDDI K79
ATF-2 (rat) SPFENEFKKASEDDI K79
K105-ac
KASEDDIkKMPLDLs
0 5
ATF-2 (human) KASEDDIkKMPLDLs K105-ac
ATF-2 (mouse) KASEDDIKKMPLDLs K87
ATF-2 (rat) KASEDDIKKMPLDLs K87
S112-p
kKMPLDLsPLAtPII
Upstream
0 85
Treatment
  • high_cell_density
  • ischemia
  • low_cell_density
  • LRRK2-IN-1
  • nocodazole
  • UV
ATF-2 (human) kKMPLDLsPLAtPII S112-p
ATF-2 (mouse) KKMPLDLsPLAtPII S94-p
ATF-2 (rat) KKMPLDLsPLATPII S94-p
T116-p
LDLsPLAtPIIRsKI
Upstream
1 40
Kinase, in vitro:
  • CDK2 (human)
Treatment
  • ischemia
  • nocodazole
ATF-2 (human) LDLsPLAtPIIRsKI T116-p
ATF-2 (mouse) LDLsPLAtPIIRSKI T98-p
ATF-2 (rat) LDLsPLATPIIRSKI T98
S121-p
LAtPIIRsKIEEPSV
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
Effects on Biological Processes:
  • transcription, induced
Kinase, in vitro:
  • PKCA (human)
  • PKCB (human)
  • PKCB iso2 (human)
Treatment
  • Go_6976
  • peptide_antagonist
  • phorbol_ester
  • retinoic_acid
ATF-2 (human) LAtPIIRsKIEEPSV S121-p
ATF-2 (mouse) LAtPIIRSKIEEPSV S103
ATF-2 (rat) LATPIIRSKIEEPSV S103
S136-p
VETTHQDsPLPHPES
0 8
ATF-2 (human) VETTHQDsPLPHPES S136-p
ATF-2 (mouse) VETTHQDsPLPHPES S118-p
ATF-2 (rat) VETTHQDSPLPHPES S118
S266
PGIPGPSSPQPVQSE
0 2
ATF-2 (human) PGIPGPSSPQPVQSE S266
ATF-2 (mouse) PGIPGPSsPQPVQSE S248-p
ATF-2 (rat) PGIPGPSSPQPVQSE S248
T283-p
MRLKAALtQQHPPVt
0 2
ATF-2 (human) MRLKAALtQQHPPVt T283-p
ATF-2 (mouse) MRLKAALtQQHPPVt T265-p
ATF-2 (rat) MRLKAALTQQHPPVT T265
T290-p
tQQHPPVtNGDTVKG
0 2
ATF-2 (human) tQQHPPVtNGDTVKG T290-p
ATF-2 (mouse) tQQHPPVtNGDTVKG T272-p
ATF-2 (rat) TQQHPPVTNGDTVKG T272
T290
tQQHPPVTNGDTVKG
0 2
ATF-2 (human) tQQHPPVTNGDTVKG T290
ATF-2 (mouse) tQQHPPVtNGDTVKG T272-gl
ATF-2 (rat) TQQHPPVTNGDTVKG T272
T305-p
HGSGLVRtQsEEsRP
0 5
ATF-2 (human) HGSGLVRtQsEEsRP T305-p
ATF-2 (mouse) HGSGLVRtQsEEsRP T287-p
ATF-2 (rat) HGSGLVRAQSEESRP A287
S307-p
SGLVRtQsEEsRPQS
0 9
ATF-2 (human) SGLVRtQsEEsRPQS S307-p
ATF-2 (mouse) SGLVRtQsEEsRPQS S289-p
ATF-2 (rat) SGLVRAQSEESRPQS S289
S310-p
VRtQsEEsRPQSLQQ
0 3
ATF-2 (human) VRtQsEEsRPQSLQQ S310-p
ATF-2 (mouse) VRtQsEEsRPQSLQQ S292-p
ATF-2 (rat) VRAQSEESRPQSLQQ S292
S321-p
SLQQPATsTTEtPAs
0 1
ATF-2 (human) SLQQPATsTTEtPAs S321-p
ATF-2 (mouse) SLQQPATSTTETPAs S303
ATF-2 (rat) SLQQPATSTTETPAs S303
T325-p
PATsTTEtPAsPAHT
0 1
ATF-2 (human) PATsTTEtPAsPAHT T325-p
ATF-2 (mouse) PATSTTETPAsPAHt T307
ATF-2 (rat) PATSTTETPAsPAHT T307
S328-p
sTTEtPAsPAHTtPQ
Upstream
0 28
Treatment
  • EGF
ATF-2 (human) sTTEtPAsPAHTtPQ S328-p
ATF-2 (mouse) STTETPAsPAHtTPQ S310-p
ATF-2 (rat) STTETPAsPAHTTPQ S310-p
T332
tPAsPAHTtPQtQST
0 2
ATF-2 (human) tPAsPAHTtPQtQST T332
ATF-2 (mouse) TPAsPAHtTPQTQNT T314-p
ATF-2 (rat) TPAsPAHTTPQTQNT T314
T333-p
PAsPAHTtPQtQSTs
0 2
ATF-2 (human) PAsPAHTtPQtQSTs T333-p
ATF-2 (mouse) PAsPAHtTPQTQNTs T315
ATF-2 (rat) PAsPAHTTPQTQNTS T315
T336-p
PAHTtPQtQSTsGRR
0 4
ATF-2 (human) PAHTtPQtQSTsGRR T336-p
ATF-2 (mouse) PAHtTPQTQNTsGRR T318
ATF-2 (rat) PAHTTPQTQNTSGRR T318
S340-p
tPQtQSTsGRRRRAA
Upstream
2 2
Kinase, in vitro:
  • PKCB (rat)
Treatment
  • peptide_antagonist
  • phorbol_ester
  • retinoic_acid
ATF-2 (human) tPQtQSTsGRRRRAA S340-p
ATF-2 (mouse) TPQTQNTsGRRRRAA S322-p
ATF-2 (rat) TPQTQNTSGRRRRAA S322
K357-ac
DPDEKRRkFLERNRA
1 0
ATF-2 (human) DPDEKRRkFLERNRA K357-ac
ATF-2 (mouse) DPDEKRRKFLERNRA K339
ATF-2 (rat) DPDEKRRKFLERNRA K339
S367-p
ERNRAAAsRCRQKRk
Upstream
2 0
Kinase, in vitro:
  • PKCB (rat)
Treatment
  • peptide_antagonist
  • phorbol_ester
  • retinoic_acid
ATF-2 (human) ERNRAAAsRCRQKRk S367-p
ATF-2 (mouse) ERNRAAASRCRQKRK S349
ATF-2 (rat) ERNRAAASRCRQKRK S349
K374-ac
sRCRQKRkVWVQSLE
1 0
ATF-2 (human) sRCRQKRkVWVQSLE K374-ac
ATF-2 (mouse) SRCRQKRKVWVQSLE K356
ATF-2 (rat) SRCRQKRKVWVQSLE K356
K409-ub
RNEVAQLkQLLLAHK
Upstream
0 5
Treatment
  • MG132
ATF-2 (human) RNEVAQLkQLLLAHK K409-ub
ATF-2 (mouse) RNEVAQLkQLLLAHK K391-ub
ATF-2 (rat) RNEVAQLKQLLLAHK K391
T431-p
QKKSGYHtADKDDSs
0 1
ATF-2 (human) QKKSGYHtADKDDSs T431-p
ATF-2 (mouse) QKKSGYHTADKDDSS T413
ATF-2 (rat) QKKSGYHTADKDDSS T413
S438-p
tADKDDSsEDIsVPS
0 1
ATF-2 (human) tADKDDSsEDIsVPS S438-p
ATF-2 (mouse) TADKDDSSEDLSVPS S420
ATF-2 (rat) TADKDDSSEDLSVPS S420
S442-p
DDSsEDIsVPSsPHt
0 1
ATF-2 (human) DDSsEDIsVPSsPHt S442-p
ATF-2 (mouse) DDSSEDLSVPSSPHT S424
ATF-2 (rat) DDSSEDLSVPSSPHT S424
S446-p
EDIsVPSsPHtEAIQ
0 2
ATF-2 (human) EDIsVPSsPHtEAIQ S446-p
ATF-2 (mouse) EDLSVPSSPHTEAIQ S428
ATF-2 (rat) EDLSVPSSPHTEAIQ S428
T449-p
sVPSsPHtEAIQHSS
0 1
ATF-2 (human) sVPSsPHtEAIQHSS T449-p
ATF-2 (mouse) SVPSSPHTEAIQHSS T431
ATF-2 (rat) SVPSSPHTEAIQHSS T431
S490-p
QSTEPALsQIVMAPS
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
Putative in vivo kinases:
  • ATM (human)
Treatment
  • ionizing_radiation
  • neocarzinostatin
  • UV
ATF-2 (human) QSTEPALsQIVMAPS S490-p
ATF-2 (mouse) QSTEPALSQIVMAPP S472
ATF-2 (rat) QSTEPALSQIVMAPS S472
S498-p
QIVMAPSsQSQPSGS
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
Putative in vivo kinases:
  • ATM (human)
Treatment
  • ionizing_radiation
  • neocarzinostatin
  • UV
ATF-2 (human) QIVMAPSsQSQPSGS S498-p
ATF-2 (mouse) QIVMAPPSQAQPSGS S480
ATF-2 (rat) QIVMAPSSQAQPSGS S480